(b) preparing a compound ~~The process of Claim 26, wherein the compound prepared is~~ of the formula

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $\text{-}(L^1)_c\text{-}P^1$, $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

P^1, P^2, P^3, and P^4 are each independently ~~sequences of pharmacologically active peptides~~ the selected peptide sequences;

L^1, L^2, L^3, and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;

wherein "peptide" refers to molecules of 2 to 40 amino acids.

47.   (Original). The process of Claim 46, wherein the compound prepared is of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

48.   (Original). The process of Claim 46, wherein the compound prepared is of the formulae

$$F^1\text{-}(L^1)_c\text{-}P^1$$

or

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2.$$

49.   (Original). The process of Claim 46, wherein F^1 is an IgG Fc domain.

50.   (Original). The process of Claim 46, wherein F^1 is an IgG1 Fc domain.

51.   (Original). The process of Claim 46, wherein F^1 comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

63.   (New). The process of Claim 46 wherein a is 1 and b is 0.

64.   (New). The process of Claim 46 wherein X^1 is $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2.$

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27.   (Canceled).

28.   (Amended). The process of Claim ~~26~~ 46, wherein ~~the preparation of the pharmacologic agent~~ step b of Claim 46 is carried out by:

    a.   preparing a gene construct comprising a nucleic acid sequence encoding the peptide selected ~~peptide and~~ in step a of claim 46 adjacent to either the N-terminus or the C-terminus of a nucleic acid sequence encoding an Fc domain; and

    b.   expressing the gene construct.

29.   (Amended). The process of Claim ~~26~~ 28, wherein the gene construct is expressed in an E. coli cell.

30 – 39. (Canceled).

40.   (Amended). The process of Claim ~~26~~ 46, wherein step a of Claim ~~26~~ 46 is carried out by a process comprising:

    a.   preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;

    b.   conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein

        i)   a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and

        ii)   a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.

41-45. (Canceled).

46.   (Amended). A process for preparing a pharmacologically active compound, which comprises:

        (a) selecting from a library at least one peptide sequence that modulates the activity of AGP-3;

65. (New). The process of Claim 63 wherein X^1 is $-(L^1)_c-P^1-(L^2)_d-P^2$.

66. (New). The process of Claim 65 wherein L^1 is $(Gly)_5$.

67. (New). The process of Claim 65 wherein L^2 is $(Gly)_5$.

68. (New). The process of Claim 66 wherein L^2 is $(Gly)_5$.

69. (New). The process of Claim 46 wherein the library is a phage display library.

70. (New). The process of Claim 65 wherein the library is a phage display library.

71. (New). The process of Claim 68 wherein the library is a phage display library.

72. (New). The process of Claim 46 wherein the library is an *E. coli* display library.

73. (New). The process of Claim 65 wherein the library is an *E. coli* display library.

74. (New). The process of Claim 46 wherein the library is a ribosome display library.

75. (New). The process of Claim 65 wherein the library is a ribosome display library.

76. (New). The process of Claim 46 wherein the library is a chemical peptide library.

77. (New). The process of Claim 65 wherein the library is a chemical peptide library.

78. (New). The process of Claim 46 wherein the library is a yeast peptide library.

79. (New). The process of Claim 65 wherein the library is a yeast peptide library.